Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease DOI Creative Commons
Yuhong Fan, Siyao Zhang, Ye Wang

и другие.

Frontiers in Endocrinology, Год журнала: 2025, Номер 15

Опубликована: Янв. 9, 2025

Non-alcoholic fatty liver disease (NAFLD) is a multisystem metabolic disorder, marked by abnormal lipid accumulation and intricate inter-organ interactions, which contribute to systemic imbalances. NAFLD may progress through several stages, including simple steatosis (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis, potentially cancer. This closely associated with disorders driven overnutrition, key pathological processes dysregulation, impaired autophagy, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, local inflammation. While hepatic metabolism in well-documented, further research into communication mechanisms crucial for deeper understanding of progression. review delves intrahepatic networks tissue-specific signaling mediators involved pathogenesis, emphasizing their impact on distal organs.

Язык: Английский

Current status and future trends of the global burden of MASLD DOI
Lei Miao, Giovanni Targher, Christopher D. Byrne

и другие.

Trends in Endocrinology and Metabolism, Год журнала: 2024, Номер 35(8), С. 697 - 707

Опубликована: Фев. 29, 2024

Язык: Английский

Процитировано

234
Role of the cGAS–STING pathway in systemic and organ-specific diseases DOI Open Access
Sladjana Skopelja‐Gardner, Jie An, Keith B. Elkon

и другие.

Nature Reviews Nephrology, Год журнала: 2022, Номер 18(9), С. 558 - 572

Опубликована: Июнь 22, 2022

Язык: Английский

Процитировано

180
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease DOI Open Access
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne

и другие.

HepatoBiliary Surgery and Nutrition, Год журнала: 2023, Номер 12(3), С. 386 - 403

Опубликована: Фев. 24, 2023

With the rising global prevalence of fatty liver disease related to metabolic dysfunction, association this common condition with chronic kidney (CKD) has become increasingly evident. In 2020, more inclusive term dysfunction-associated (MAFLD) was proposed replace non-alcoholic (NAFLD). The observed between MAFLD and CKD our understanding that can be a consequence underlying dysfunction support notion individuals are at higher risk having developing compared those without MAFLD. However, date, there is no appropriate guidance on in Furthermore, been little attention paid link Nephrology community.Using Delphi-based approach, multidisciplinary panel 50 international experts from 26 countries reached consensus some open research questions regarding CKD.This statement provided epidemiology, mechanisms, management treatment CKD, as well relationship severity which establish framework for early prevention these two interconnected diseases.

Язык: Английский

Процитировано

61
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives DOI Creative Commons
Shang‐Chin Huang, Chun‐Jen Liu

Clinical and Molecular Hepatology, Год журнала: 2023, Номер 29(2), С. 320 - 331

Опубликована: Фев. 2, 2023

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although is a well-known risk factor for adverse outcomes like cirrhosis hepatocellular carcinoma, its interactions with virus (HBV) clinical impacts seem complex. presence hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated injury. In contrast, associated co-morbidities diabetes mellitus or obesity increase developing outcomes. These findings implicate that components MAFLD have diverse effects on manifestations CHB. To this end, strategy proposed managing concurrent CHB MAFLD. This review article discusses updated evidence regarding prevalence, between HBV, impacts, management strategies, aiming at optimizing holistic health care in population.

Язык: Английский

Процитировано

46
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases DOI Creative Commons

Reddemma Sandireddy,

Suganya Sakthivel,

Priyanka Gupta

и другие.

Frontiers in Cell and Developmental Biology, Год журнала: 2024, Номер 12

Опубликована: Июль 16, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty (NAFLD), is the most common disorder worldwide, with an estimated global prevalence of more than 31%. steatohepatitis (MASH), formerly (NASH), a progressive form MASLD characterized by hepatic steatosis, inflammation, and fibrosis. This review aims to provide comprehensive analysis extrahepatic manifestations MASH, focusing on chronic diseases related cardiovascular, muscular, renal systems. A systematic published studies literature was conducted summarize findings systemic impacts MASH. The focused association MASH metabolic comorbidities, cardiovascular mortality, sarcopenia, kidney disease. Mechanistic insights into concept lipotoxic inflammatory "spill over" from MASH-affected were also explored. are highly associated (50%-80%) other comorbidities such impaired insulin response, type 2 diabetes, dyslipidemia, hypertriglyceridemia, hypertension. Furthermore, 90% obese patients diabetes have Data suggest that in middle-aged individuals (especially those aged 45-54), independent risk factor for plays crucial role mediating pathological effects observed. Understanding multifaceted impact heart, muscle, early detection stratification. knowledge timely implementing management strategies addressing multi-organ involvement pathogenesis.

Язык: Английский

Процитировано

32
An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease DOI
Le Zhang, Mortada El‐Shabrawi, Louise A. Baur

и другие.

Med, Год журнала: 2024, Номер 5(7), С. 797 - 815.e2

Опубликована: Апрель 26, 2024

Язык: Английский

Процитировано

22
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? DOI Open Access
Kamila Kasprzak‐Drozd, Przemysław Niziński,

Paulina Kasprzak

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(7), С. 3746 - 3746

Опубликована: Март 27, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is influenced by a variety of factors, including environmental and genetic factors. The most significant outcome the alteration free fatty acid triglyceride metabolism. Lipotoxicity, impaired autophagy, chronic inflammation, oxidative stress, as well coexisting insulin resistance, obesity, changes in composition gut microbiota, are also considered crucial factors pathogenesis MASLD. Resveratrol polyphenolic compound that belongs to stilbene subgroup. This review summarises available information on therapeutic effects resveratrol against has demonstrated promising antisteatotic, antioxidant, anti-inflammatory activities cells vitro animal studies. been associated with inhibiting NF-κB pathway, activating SIRT-1 AMPK pathways, normalizing intestinal microbiome, alleviating inflammation. However, clinical studies have yielded inconclusive results regarding efficacy hepatic steatosis or reducing any parameters found MASLD human patients. lack homogeneity between studies, low bioavailability resveratrol, population variability when compared models could be reasons for this.

Язык: Английский

Процитировано

20
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease DOI Creative Commons
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu

и другие.

Hepatology International, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

Язык: Английский

Процитировано

5
Steatotic liver disease, MASLD and risk of chronic kidney disease DOI Creative Commons
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne

и другие.

Diabetes & Metabolism, Год журнала: 2023, Номер 50(1), С. 101506 - 101506

Опубликована: Дек. 21, 2023

With the rising tide of fatty liver disease related to metabolic dysfunction worldwide, association this common with chronic kidney (CKD) has become increasingly evident. In 2020, more inclusive term dysfunction-associated (MAFLD) was proposed replace old nonalcoholic (NAFLD). 2023, a modified Delphi process led by three large pan-national associations. There consensus change nomenclature and definition include presence at least one five cardiometabolic risk factors as diagnostic criteria. The name chosen NAFLD steatotic (MASLD). from MAFLD then MASLD resulted in reappraisal epidemiological trends associations developing CKD. observed between MAFLD/MASLD CKD our understanding that can be an epiphenomenon linked underlying support notion individuals are substantially higher incident than those without MASLD. This narrative review provides overview literature on (a) evolution criteria for diagnosing highly prevalent disease, (b) evidence linking CKD, (c) mechanisms which (and strongly MASLD) may increase (d) potential drug treatments benefit both

Язык: Английский

Процитировано

43
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications DOI Open Access
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(21), С. 13320 - 13320

Опубликована: Ноя. 1, 2022

Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic worldwide, affecting up to ~30% adult populations. NAFLD defines a spectrum progressive conditions ranging from simple steatosis nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma, which often occur in close bidirectional associations with metabolic disorders. Chronic kidney (CKD) is characterized by anatomic and/or functional renal damage, ultimately resulting reduced glomerular filtration rate. The physiological axis linking kidneys passes unnoticed until clinically significant portal hypertension, as major complication becomes apparent form ascites, refractory or hepatorenal syndrome. However, extensive evidence accumulated since 2008 indicates that noncirrhotic associated higher risk incident CKD, independent obesity, type 2 diabetes, other factors. In addition, subclinical hypertension been demonstrated NAFLD, potential adverse impact on vasoregulation. mechanisms underlying this association remain unexplored substantial extent. With background, review we discuss current showing strong between putative biological underpinning association. We also depth pathogenic role reflex, may be triggered poorly investigated but promising research topic. Finally, address emerging pharmacotherapies for beneficially affect developing CKD individuals NAFLD.

Язык: Английский

Процитировано

42